Vasopressin antagonism in heart failure.
Explore this paper's citation graph
Summary
The development of effective nonpeptide antagonists to both the V1a and V2 receptors for AVP now allows for testing the hypotheses that interfering with AVP-mediated signaling could be beneficial in HF.
- Type
- review
- Published
- 2005-11-15
- Cited by
- 228
- References
- 61
- Access
- Open access
- OpenAlex
- https://openalex.org/W1970134098
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:23994032
Keywords
Medicine, Vasopressin, Heart failure, Aldosterone, Arginine vasopressin receptor 2
References
- Vasopressin and Arterial Pressure Regulation Special Lecture
- Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure.
- Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.
- Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril.
- Prognostic value of hyponatremia in hospitalized patients with worsening heart failure - insights from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME - CHF)
- Renal function, neurohormonal activation, and survival in patients with chronic heart failure.
- Increased plasma arginine vasopressin levels in patients with congestive heart failure.
- Vasopressin: a therapeutic target in congestive heart failure?
- Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs.
- Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition.
- Hemodynamic effects of infused arginine vasopressin in congestive heart failure.
- Antidiuretic hormone in congestive heart failure.
- Plasma ADH level in patients with chronic congestive heart failure.
- Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents.
- The neurohumoral axis in congestive heart failure.
- Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis.
- Novel Vasopressin V1A and V2 Antagonist (Conivaptan) Increases Serum Sodium Concentration and Effective Water Clearance in Patients with Hyponatremia
- Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor.
- Furosemide and the progression of left ventricular dysfunction in experimental heart failure.
- Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
Cited by
- Beyond cardiac troponin: recent advances in the development of alternative biomarkers for cardiovascular disease
- What Is Evidence-Based, What Is New in Medical Therapy of Acute Heart Failure?
- Biomarcadores en Neumonías
- Emerging therapies for the management of decompensated heart failure: from bench to bedside.
- Implication des espèces réactives de l'oxygène dans le contrôle central de l'osmorégulation
- Rôle du récepteur EphA4 dans la plasticité structurale neurono-gliale du noyau supraoptique à la suite d’un régime à l’eau salée
- The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials
- Role of vasopressin in rat distal colon function
- Mecanismes d’acció de l’aldosterona i de la vasopressina en la regulació de les funcions del còlon
- EMERGING DRUG THERAPIES FOR HEART FAILURE
- Contrôle noradrénergique de la plasticité neurochimique et structurale dans le noyau supra-optique de l'hypothalamus chez la souris
- Pathophysiology of volume overload in acute heart failure syndromes
- Conivaptan therapy in an infant with severe hyponatremia and congestive heart failure.
- Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
- Perspectives for the treatment of anemia in heart failure: is there a role for vasopressin antagonists?
- Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.
- Current Approach to Decongestive Therapy in Acute Heart Failure
- Correction of hyponatremia by tolvaptan before left ventricular assist device implantation.
- Endogenous stress response in Tako‐Tsubo cardiomyopathy and acute myocardial infarction
- Biomarkers in Acute Decompensated Heart Failure
Related papers
- [From hyponatremia to tolvaptan].
- Hyponatremia, Heart Failure, and the Role of Tolvaptan
- Unpredictable Nature of Tolvaptan in Treatment of Hypervolemic Hyponatremia: Case Review on Role of Vaptans
- Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
- V2 Receptor Antagonist; Tolvaptan
- Effectiveness of Tolvaptan Treatment in Hyponatremic Patients
- Tolvaptan, a vasopressin V2 receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)
- Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial
- Vasopressin antagonism: a future treatment option in heart failure.